Our Products

Espero is focused on branded specialty pharmaceuticals designed to treat a wide spectrum of conditions from complex and chronic to serious and potentially life-threatening. Whether at the clinical stage, near product launch, or currently on the market, Espero’s targeted sales force and multichannel approach provide an effective marketing strategy for every product in our portfolio.

Espero’s wholly owned subsidiary, Jacksonville Pharmaceuticals, handles our generic prescription products. Jacksonville is committed to offering quality and value to patients with the products we bring to market.

Espero Pharma Products

GONITRO™

The FDA recently approved GONITRO™ (nitroglycerin) sublingual powder, the first and only short-acting nitrate in a stabilized crystal granule form available in single dose packets. To learn more about GONITRO, please visit the brand website, www.GoNitroRx.com. You may also refer to the Full Prescribing Information for more information including safety information.
Espero Pharma Products


Espero Pharma Products

Nitrolingual®

Our other marketed products are Nitrolingual® Pumpspray and its authorized generic, nitroglycerin spray. For more information, please visit the brand website, www.nitrolingual.com.


Espero Pharma Products

DURLAZA®

DURLAZA (aspirin) Extended Release Capsules, for oral use, was approved by the FDA in September 2015. Espero Pharmaceuticals acquired the global rights to DURLAZA in February 2017. DURLAZA is indicated to:

  1. Reduce the risk of death and myocardial infarction (MI) in patients with chronic coronary artery disease, such as patients with a history of MI or unstable angina pectoris or with chronic stable angina.
  2. Reduce the risk of death and recurrent stroke in patients who have had an ischemic stroke or transient ischemic attack.

Limitation of Use: Use immediate-release aspirin, not DURLAZA in situations where a rapid onset of action is required (such as acute treatment of myocardial infarction or before percutaneous coronary intervention). To learn more about DURLAZA, please visit the brand website, www.durlaza.com. You may also refer to the Full Prescribing Information for more information including safety information.


In addition to growing our current library of products, we are actively looking to acquire or in-license late stage development and commercialized products in the following therapeutic areas:
  • Cardiology
  • Other Specialty Markets

Product Adverse Events or Product Complaints:
Email: Medinfo.espero@apcerls.com
Call Toll-Free: (800) 235-6520
You are encouraged to report negative side effects of prescription drugs to the FDA.
Visit www.fda.gov/medwatch or call 1-800-FDA-1088 FREE.